Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study
Marc Ferrante(Universitair Ziekenhuis Leuven), Luciana Teixeira de Campos, Frédérick Durand(Eli Lilly (United States)), Fernanda Dorado, Anthony Croft(QIMR Berghofer Medical Research Institute), J. Razera, Rupert W. Leong(The University of Sydney), Britta Siegmund(Humboldt-Universität zu Berlin), Emiliano Tron, Vipul Jairath(McMaster University), Marijana Protić(Eli Lilly (United States)), Zhantao Lin(Eli Lilly (United States)), Simon Ghaly(UNSW Sydney), Sonja M. Bragg(Eli Lilly (United States)), Carlos Fernando de Magalhães Francesconi, Lena Thin(The University of Western Australia), Jonathan Soldera(Lear (United States)), Geert D’Haens(Amsterdam University Medical Centers), Britt Christensen, Fabio Luiz Maximiano, Nathan Morris(Case Western Reserve University), Rodrigo Rocco, Carolina Baía, Sandra Di Felice Boratto, Hilde Carlier(Eli Lilly (United States)), D. Poli, Sonja Heeren, Joaquim Simões Neto, Subrata Ghosh, Minhu Chen(Sun Yat-sen University), Michelle Ugolini Lopes(National Institute of Agricultural Botany), Alexander De Sa Rolim, Peter Bossuyt(Imelda Hospital), Bruce E Sands, Wallace Crandall, Walter Reinisch(Medical University of Vienna), Robert Koch, Tadakazu Hisamatsu(Kyorin University), A D S Carlos, C. Clemente, Hansjoerg Seltenreich(University of the Sunshine Coast), Emily Hon(Eli Lilly (United States)), Lígia Yukie Sassaki
Cited by 107
Related Papers
The Treatment-Naive Microbiome in New-Onset Crohn’s Disease
|Cell Host & Microbe|2014|3.3k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k